Chile highlights progress of Cuban Covid-19 vaccines
26 de febrero de 2021, 10:14Santiago de Chile, Feb 26 (Prensa Latina) The progress of Cuba's Covid-19 vaccine candidates was highlighted by emol.cl, which also noted the international recognition of Cuba's technology industry.
The site issued a report stating that the vaccines Soberana 02 and Abdala, two of the four being developed in Cuba, will be the first in Latin America to begin the third and final phase of clinical trials to evaluate their efficiency on a large scale.
Also according to the report, Cuban laboratories are already producing hundreds of thousands of doses necessary to carry out the last phase of the trials of both candidates, developed by the Finlay Institute of Vaccines (Soberana) and the Center for Genetic Engineering and Biotechnology (Abdala), respectively, and have already proved their safety during the previous stage.
The director of the Finlay Institute, Vicente Verez, explained to the Spanish agency EFE that in the case of Soberana 02, two trials will be carried out in parallel, one with 44 thousand participants in Havana and another that will include more than a million volunteers.
Emol.cl reports that the 340,000 doses necessary for the third phase of trials are being produced by the Center for Molecular Immunology, which, in the words of its director, Eduardo Ojito, is capable of meeting the goal.
After providing details on the immunization mechanisms used in both vaccines, the report affirms that Cuba has a recognized biotechnology and pharmaceutical industry that includes vaccines against diseases such as meningitis, and therapeutics for lung cancer and solid tumors, among others.
ef/llp/mem/rc
